Navigation Links
Nuvelo Reports Third Quarter 2008 Financial Results
Date:10/30/2008

SAN CARLOS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced third quarter 2008 financial results and accomplishments.

For the third quarter ended September 30, 2008, Nuvelo reported a net loss of $8.5 million or $0.16 per share, compared with net loss of $14.4 million or $0.27 per share for the same period in 2007. For the nine months ended September 30, 2008, Nuvelo reported a net loss of $27.2 million or $0.51 per share, compared with net loss of $0.7 million or $0.01 per share for the same period in 2007. Net cash used in operating activities was $10.8 million for the third quarter of 2008 and $38.2 million for the first nine months of 2008. As of September 30, 2008, Nuvelo had $65.1 million in cash and cash equivalents, marketable securities and restricted cash.

Revenues for both the third quarter of 2008 and 2007 were $0.1 million. Revenues for the nine months ended September 30, 2008 were $15.2 million, compared with revenues of $46.8 million for the same period in 2007. $15.0 million of the revenues for the nine months ended September 30, 2008 was a result of the recognition of the termination payment received from Bayer in June 2007. This payment had been recorded as deferred revenue and was recognized as revenue in May 2008. $45.8 million of the revenues recorded in the nine months ended September 30, 2007 was a result of the termination of Nuvelo's collaboration agreement with Bayer in June 2007. Nuvelo had originally recorded the $50.0 million up-front license fee that it received from Bayer in January 2006 as deferred revenue.

Total operating expenses for the third quarter of 2008 were $9.1 million, compared with $16.0 million for the same period in 2007. Total operati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
3. Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting
4. Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program
5. Nuvelo to Present at Jefferies 2nd Annual Healthcare Conference
6. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
7. Haemacure Reports Third Quarter 2007 Results
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Kim Kardashian Says Real Women Keep Their Curves With 'Fit In Your Jeans By Friday' 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:New Jersey IT Services Firm to Host Educational Luncheon Event, EMR & Information Technology for the Specialty Medical Practice 2Health News:New Jersey IT Services Firm to Host Educational Luncheon Event, EMR & Information Technology for the Specialty Medical Practice 3Health News:Practicing Clinicians Exchange Forms Partnership With Restless Legs Syndrome Foundation 2Health News:Practicing Clinicians Exchange Forms Partnership With Restless Legs Syndrome Foundation 3Health News:Genoptix Announces Participation at the Bank of America and Merrill Lynch 2009 Annual Health Care Conference 2Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 2Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 3Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 4Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 5Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 6Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 7Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 8Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 9Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 10Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 11
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Policy transparency key to saving worlds fisheries 8955 1Policy transparency key to saving worlds fisheries 8955 2Policy transparency key to saving worlds fisheries 8955 3Policy transparency key to saving worlds fisheries 8955 4Policy transparency key to saving worlds fisheries 8955 5Domestic Violence Expert Comments on Chris Brown Plea Deal 49697 1Domestic Violence Expert Comments on Chris Brown Plea Deal 49697 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 1Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 3